참고문헌
- Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane database of systematic reviews (Online). 2006(1): CD001190
- Rogers SL. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia and geriatric cognitive disorders. 1998;9 Suppl 3:29-42
- Roman GC, Rogers SJ. Donepezil: a clinical review of current and emerging indications. Expert opinion on pharmacotherapy. 2004;5 (1):161-180 https://doi.org/10.1517/14656566.5.1.161
- Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. The Annals of pharmacotherapy. 2001;35(2):202-205 https://doi.org/10.1345/aph.10192
- Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane database of systematic reviews (Online). 2004(1):CD00 4395
- Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest. 2008;133(3):677-683 https://doi.org/10.1378/chest.07-1446
- Riedel G, Kang SH, Choi DY, Platt B. Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behavioural brain research. 2009;204(1):217-225 https://doi.org/10.1016/j.bbr.2009.06.012
- Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of child and adolescent psychopharmacology. 2011;21(1):43-50 https://doi.org/10.1089/cap.2010.0024
-
PfizerCanada Inc.. PRODUCT MONOGRAPH
$PrARICEPT^{(R)}$ (donepezil hydrochloride) Tablets 5 and 10 mg PrARICEPT RDTTM (donepezil hydrochloride) Rapidly Disintegrating Tablets 5 and 10 mg Cholinesterase Inhibitor. FDA Submission Control No: 107207. 2007 - Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. Journal of psychopharmacology (Oxford, England). 2000; 14(4):406-408 https://doi.org/10.1177/026988110001400410
- Benazzi F. Mania associated with donepezil. Journal of psychiatry & neuroscience : JPN. 1999;24(5):468-469
- Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. International psychogeriatrics / IPA. 2008;20(4):800-806
- Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dementia and geriatric cognitive disorders. 2009;28(5):389-403 https://doi.org/10.1159/000255578
- Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. British journal of clinical pharmacology. 1998;46 Suppl 1:25-29
- Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. British journal of clinical pharmacology. 1998;46 Suppl 1:30-34
- Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. Journal of clinical pharmacology. 2004;44(5) :538-542 https://doi.org/10.1177/0091270004264161
- Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. British journal of clinical pharmacology. 1998;46 Suppl 1:40-44
- Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. British journal of clinical pharmacology. 1998;46 Suppl 1:35-39
- Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. British journal of clinical pharmacology. 1998;46 Suppl 1:45-50
- Kim YH, Bae MJ. The effect of Kong Jin Dan on the lipid metabolism in rats fed high fat-diet. J East-West Med. 2001;14 :61-78
- Kim YS, Lee JD, Kim CH, Choi DY, Park DS, Nam SS, Kang SK. The Effect of Gongjindan Aqua-acupuncture on the CD4+ T cell count at al. in rats were administered with MTX. J Korean Acup Moxi Soc. 1999;16:179-202
- Choi KH, Park CS. An analysis of the Gongjindan's ingredients and its efficacy on anti-oxidation. Korea J Herbology. 2007 ;22(2):51-63
- Seong KM, Hae RK, Song BK. The effect of Gongjin-dan on gliosis in middle cerebral artery occlusion (MCAO) rats. J Korea Oriental Int Med. 2009;30:674-684
- Hwang SM, Chung DK. The Effects of KongJin-Dan (KJD) on the Alzheimer's disease model induced by CT105. J Oriental Neuropsychiatry. 2004;15(2):103-118
- Jung HC, Jang HJ, Sung WY, Lee SH, Son JH, Han SH. A study of Gongjin-dan in patients with mild dementia of Alzheimer type. J Oriental Neuropsychiatry. 2004;15 (2):141-148
- Park MY, Kim JD, Ku SK. Single Oral Dose Toxicity Test of Kong-Jin-Dan, a Polyherbal Formula in ICR Mice. Biomolecules & Therapeutics. 2007;15(4):245-251
- Ku S-K. Micronucleus Test of Kong- Jin-Dan, a Polyherbal Formula, in Bone Marrow Cells of Male ICR Mice. Toxicological Research. 2008;24(3):213-218 https://doi.org/10.5487/TR.2008.24.3.213
- Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel-Dekker; 1982.
- Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. Journal of pharmacokinetics and biopharmaceutics. 1988;16(3) :303-309
- Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. Journal of pharmacokinetics and biopharmaceutics. 1978;6(6):539-546
- Dickinson BD. UHC drug monograph: Donepezil. UHC (University Health System Consortium) Services Corporation. 1996:1-14
- Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, Morishita N. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. International journal of clinical pharmacology, therapy, and toxicology. 1993;31(5):223-229
- Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. British journal of clinical pharmacology. 1998;46 Suppl 1:13-18
- Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. British journal of clinical pharmacology. 1998;46 Suppl 1:19-24
- Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50(1):136-145 https://doi.org/10.1212/WNL.50.1.136
- Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1998 ;8(1):67-75 https://doi.org/10.1016/S0924-977X(97)00079-5
- Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug metabolism and disposition: the biological fate of chemicals. 1999;27(12) :1406-1414
- Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. British journal of clinical pharmacology. 1998;46 Suppl 1:51-55